Prolight Diagnostics (PRLD) Q3 2025 earnings summary

Executive summary

• No net sales reported for Q3 or the nine-month period; company remains in product development phase.

• Operating losses increased year-over-year, reflecting intensified product development and higher personnel costs.

• Fully subscribed rights issue raised SEK 100.3 million, strengthening liquidity for ongoing development.

• Key milestones include patent grants in Japan and Europe, and showcasing the Psyros system prototype at a major industry congress.

Financial highlights

• Q3 operating profit (EBIT) was -13,908 TSEK, down from -8,731 TSEK in Q3 2024; nine-month EBIT was -37,262 TSEK versus -28,760 TSEK year-over-year.

• Cash flow from operating activities for Q3 was -12,558 TSEK; for the nine months, -26,342 TSEK.

• Cash and cash equivalents at quarter-end were 59,590 TSEK, up from 14,966 TSEK a year earlier.

• Equity ratio improved to 89% from 77% at the end of the previous year.

• Earnings per share remained at -0.01 SEK for Q3 and -0.03 SEK for the nine-month period.

Outlook and guidance

• Clinical performance study initiation postponed to 2026 (from late 2025) to allow for thorough preparations.

• Regulatory approval and commercialization now expected in 2027.

• Company aims to reach assay design freeze and start pilot instrument production in the current quarter.